NIH to test Pfizer’s Paxlovid, other treatments as potential long Covid therapies

NIH to test Pfizer’s Paxlovid, other treatments as potential long Covid therapies


Paxlovid, Pfizer’s anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken October 7, 2022.

Wolfgang Rattay | Reuters

The National Institutes of Health said Monday it launched mid-stage clinical trials to test at least four treatments, including Pfizer‘s antiviral Covid-19 pill Paxlovid, as potential therapies for long Covid. 

There is no proven treatment for the condition, which refers to symptoms that continue or develop in the weeks or months following an initial Covid infection. It affects an estimated 23 million Americans.

related investing news

This little-known pharma stock can rally 50%, Citi says

CNBC Pro

Health care providers typically try to treat the often debilitating symptoms associated with long Covid, such as chronic pain, memory loss and intense fatigue. But the lack of a specific long Covid treatment pushes some patients to seek unproven – and potentially dangerous – remedies for the condition. 

“We know that when patients are suffering, we can never move fast enough,” said acting NIH director Lawrence Tabak. “NIH is committed to a highly coordinated and scientifically rigorous approach to find treatments that will provide relief for the millions of people living with long COVID.”

NIH will test the safety and effectiveness of the treatments – which include both drugs and medical devices – in groups of 100 to 300 patients with long Covid symptoms. 

The first part of the phase two trial will test a longer dosing regimen of Paxlovid to see if it improves long Covid symptoms. 

Patients typically take Paxlovid within five days of developing Covid symptoms to reduce their risk of hospitalization or death, according to the Food and Drug Administration’s approval of the drug in May. To complete a full course of Paxlovid, patients must take three pills twice a day for five days. 

NIH said another part of the study will also test for brain fog and memory-related symptoms.

The agency will test medical treatments like a web-based brain training program called BrainHQ and a device that uses a small electric current to stimulate brain activity. 

NIH expects to launch additional clinical trials to test at least seven more treatments “in the coming months.” 



Source

Here are the retailers raising prices as Trump tariffs take hold
Business

Here are the retailers raising prices as Trump tariffs take hold

A person picks out clothing in a store as retailers compete to attract shoppers and try to maintain margins on Black Friday, one of the busiest shopping days of the year, at Woodbury Common Premium Outlets in Central Valley, New York, U.S. November 24, 2023.  Vincent Alban | Reuters Consumers who hoped tariffs would not […]

Read More
This is why Jamie Dimon is so gloomy on the economy
Business

This is why Jamie Dimon is so gloomy on the economy

Jamie Dimon, CEO of JPMorgan Chase, testifies during the Senate Banking, Housing and Urban Affairs Committee hearing titled Annual Oversight of Wall Street Firms, in the Hart Building on Dec. 6, 2023. Tom Williams | Cq-roll Call, Inc. | Getty Images The more Jamie Dimon worries, the better his bank seems to do. As JPMorgan […]

Read More
Summer rentals in the Hamptons are down 30%
Business

Summer rentals in the Hamptons are down 30%

Key Points Summer rentals in the Hamptons are down 30% from the same period in previous years, according to Judi Desiderio of William Raveis Real Estate. Brokers who focus on ultra-high-end rentals are seeing an even bigger drop and say their rental business is down between 50% and 75%. Some renters may be holding out […]

Read More